Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 10Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Cisplatin 30Radiotherapy 24pembrolizumab 21Cetuximab 21Docetaxel 13Fluorouracil 12Radiotherapy, Intensity-Modulated 10Paclitaxel 9Radiation 8Nivolumab 7Everolimus 7Carboplatin 7Oxaliplatin 6Gemcitabine 5Surgical Procedures, Operative 4Radiosurgery 4Magnetic Resonance Spectroscopy 4Gefitinib 4Erlotinib Hydrochloride 4Amifostine 4Pemetrexed 3Filgrastim 3Capecitabine 3Bleomycin 3Biopsy 3zalutumumab 2spartalizumab 2pegfilgrastim 2niraparib 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Head and Neck Neoplasms × spartalizumab × Clear all
NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis

Phase 2 Terminated
315 enrolled 73 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

SecuraBio

Phase 1/2 Terminated
2 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡